DrugPatentWatch Database Preview
Suvorexant - Generic Drug Details
» See Plans and Pricing
What are the generic drug sources for suvorexant and what is the scope of patent protection?
Suvorexant
is the generic ingredient in one branded drug marketed by Merck Sharp Dohme and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Suvorexant has seventy-five patent family members in thirty-seven countries.
One supplier is listed for this compound.
Summary for suvorexant
| International Patents: | 75 |
| US Patents: | 2 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 52 |
| Clinical Trials: | 42 |
| Patent Applications: | 62 |
| DailyMed Link: | suvorexant at DailyMed |
Recent Clinical Trials for suvorexant
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| The Scripps Research Institute | Phase 2 |
| Henry Ford Health System | Phase 2 |
Pharmacology for suvorexant
| Drug Class | Orexin Receptor Antagonist |
| Mechanism of Action | Orexin Receptor Antagonists P-Glycoprotein Inhibitors Cytochrome P450 3A Inhibitors |
US Patents and Regulatory Information for suvorexant
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | BELSOMRA | suvorexant | TABLET;ORAL | 204569-003 | Aug 13, 2014 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Merck Sharp Dohme | BELSOMRA | suvorexant | TABLET;ORAL | 204569-004 | Aug 13, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Merck Sharp Dohme | BELSOMRA | suvorexant | TABLET;ORAL | 204569-002 | Aug 13, 2014 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Merck Sharp Dohme | BELSOMRA | suvorexant | TABLET;ORAL | 204569-001 | Aug 13, 2014 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Merck Sharp Dohme | BELSOMRA | suvorexant | TABLET;ORAL | 204569-004 | Aug 13, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Merck Sharp Dohme | BELSOMRA | suvorexant | TABLET;ORAL | 204569-001 | Aug 13, 2014 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for suvorexant
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2089382 | Start Trial |
| Taiwan | I513696 | Start Trial |
| South Africa | 200903334 | Start Trial |
| Chile | 2007003441 | Start Trial |
| Mexico | 2014014644 | Start Trial |
| China | 101627028 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2020 - 2021
NCE-1 Patent Challenge Dates 2020 - 2021
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2020, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
